Lexeo Acquires Mantle Therapeutics, Adds Strategic Collaborations in Friedreich Ataxia
LXEO is trading near its 52-week low of $3.99 (4.8% above the low).
Summary
Lexeo Therapeutics is acquiring Mantle Therapeutics for an upfront payment of $8.3M, consisting of $5.3M cash and $3M stock, plus a $1M additional cash payment and up to $12M in milestone payments over 12 years, and announcing multiple new strategic collaborations to expand its leadership in Friedreich Ataxia. Key stockholders holding 76.1% of Mantle shares agreed to vote in favor. The collaborations will evaluate gene therapy sequential dosing following treatment with LX2006. The acquisition and partnerships strengthen Lexeo's pipeline in a rare disease area where it has the SUNRISE-FA 2 pivotal trial for LX2006 underway. The news follows recent FDA RMAT designation for LX2020 and extends the company's cash runway into 2028. Lexeo has a market cap around $335M and is trading near its 52-week low. No other financial terms were disclosed.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The merger agreement provides $5.3M cash and $3M stock upfront, plus a $1M additional cash payment and up to $12M in milestone payments over 12 years. Key stockholders holding 76.1% of Mantle shares agreed to vote in favor.
At the time of this announcement, LXEO was trading at $4.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $334.7M. The 52-week trading range was $3.99 to $10.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.